Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

IMPORTANCE: Second-line treatment with chemotherapy plus bevacizumab or cetuximab is a valid option for metastatic colorectal cancer. OBJECTIVE: To evaluate the progression-free survival (PFS) rate at 4 months with chemotherapy plus bevacizumab vs cetuximab for patients with progression of metastati...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Bennouna, Jaafar, Hiret, Sandrine, Bertaut, Aurelie, Bouché, Olivier, Deplanque, Gael, Borel, Christian, François, Eric, Conroy, Thierry, Ghiringhelli, François, des Guetz, Gaëtan, Seitz, Jean-François, Artru, Pascal, Hebbar, Mohamed, Stanbury, Trevor, Denis, Marc G., Adenis, Antoine, Borg, Christophe
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2018
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440242/
https://ncbi.nlm.nih.gov/pubmed/30422156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4465
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares